Non-Insulin Therapies for Diabetes Market Report

Europe Non-Insulin Therapies for Diabetes Market Size, Status and Forecast 2014-2026

  • POSTDATE：Dec 29, 2019
  • PAGES：169
  • REPORT CODE：GMM416573
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Non-Insulin Therapies for Diabetes market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 3.5% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Non-Insulin Therapies for Diabetes Market Segmentations:

    By Player:

    • Intarcia Therapeutics

    • Luye Pharma Group

    • Eli Lilly

    • Jiangsu Hansoh Pharmaceutical

    • Merck

    • Sumitomo Dainippon Pharma

    • Novo Nordisk

    • Eurofarma

    • Pfizer

    • Alkem Labs

    • GSK

    • Takeda

    • Dong-A Pharmaceutical

    • Uni-Bio Science Group

    • Jiangsu Hengrui Medicine

    • SatRx

    • Servier

    • Emisphere

    • 3SBio

    • Geropharm

    By Type:

    • Alpha-glucosidase Inhibitors

    • Amylin Agonists

    • Biguanides

    • Dipeptidyl Peptidase-4 (DPP4) Inhibitors

    • Glinides / Meglitinides

    • GLP-1 Analogs / GLP-1 Agonists

    • Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors

    • Sulfonylureas

    • Thiazolidinediones

    • Others

    By End-User:

    • Hospital Pharmacy

    • Retail Pharmacies

    • Online Pharmacy

    • Others

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Non-Insulin Therapies for Diabetes Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Alpha-glucosidase Inhibitors from 2014 to 2026

    • 1.3.2 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Amylin Agonists from 2014 to 2026

    • 1.3.3 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Biguanides from 2014 to 2026

    • 1.3.4 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Dipeptidyl Peptidase-4 (DPP4) Inhibitors from 2014 to 2026

    • 1.3.5 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Glinides / Meglitinides from 2014 to 2026

    • 1.3.6 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of GLP-1 Analogs / GLP-1 Agonists from 2014 to 2026

    • 1.3.7 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors from 2014 to 2026

    • 1.3.8 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Sulfonylureas from 2014 to 2026

    • 1.3.9 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Thiazolidinediones from 2014 to 2026

    • 1.3.10 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Others from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Hospital Pharmacy from 2014 to 2026

    • 1.4.2 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Retail Pharmacies from 2014 to 2026

    • 1.4.3 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Online Pharmacy from 2014 to 2026

    • 1.4.4 Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Others from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Non-Insulin Therapies for Diabetes Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Non-Insulin Therapies for Diabetes by Major Types

      • 3.4.1 Market Size and Growth Rate of Alpha-glucosidase Inhibitors

      • 3.4.2 Market Size and Growth Rate of Amylin Agonists

      • 3.4.3 Market Size and Growth Rate of Biguanides

      • 3.4.4 Market Size and Growth Rate of Dipeptidyl Peptidase-4 (DPP4) Inhibitors

      • 3.4.5 Market Size and Growth Rate of Glinides / Meglitinides

      • 3.4.6 Market Size and Growth Rate of GLP-1 Analogs / GLP-1 Agonists

      • 3.4.7 Market Size and Growth Rate of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors

      • 3.4.8 Market Size and Growth Rate of Sulfonylureas

      • 3.4.9 Market Size and Growth Rate of Thiazolidinediones

      • 3.4.10 Market Size and Growth Rate of Others

    4 Segmentation of Non-Insulin Therapies for Diabetes Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Non-Insulin Therapies for Diabetes by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Non-Insulin Therapies for Diabetes for Hospital Pharmacy

      • 4.4.2 Market Size and Growth Rate of Non-Insulin Therapies for Diabetes for Retail Pharmacies

      • 4.4.3 Market Size and Growth Rate of Non-Insulin Therapies for Diabetes for Online Pharmacy

      • 4.4.4 Market Size and Growth Rate of Non-Insulin Therapies for Diabetes for Others

    5 Market Analysis by Major Regions

    • 5.1 Europe Non-Insulin Therapies for Diabetes Production Analysis by Top Regions

    • 5.2 Europe Non-Insulin Therapies for Diabetes Consumption Analysis by Top Regions

    • 5.3 Europe Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.3 France Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    6 Product Circulation of Non-Insulin Therapies for Diabetes Market among Top Countries

    • 6.1 Top 5 Export Countries in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Non-Insulin Therapies for Diabetes Landscape Analysis

    • 7.1 Germany Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 7.2 Germany Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    8. UK Non-Insulin Therapies for Diabetes Landscape Analysis

    • 8.1 UK Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 8.2 UK Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    9. France Non-Insulin Therapies for Diabetes Landscape Analysis

    • 9.1 France Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 9.2 France Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    10. Italy Non-Insulin Therapies for Diabetes Landscape Analysis

    • 10.1 Italy Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 10.2 Italy Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    11. Spain Non-Insulin Therapies for Diabetes Landscape Analysis

    • 11.1 Spain Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 11.2 Spain Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    12. Poland Non-Insulin Therapies for Diabetes Landscape Analysis

    • 12.1 Poland Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 12.2 Poland Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    13. Russia Non-Insulin Therapies for Diabetes Landscape Analysis

    • 13.1 Russia Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 13.2 Russia Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    14. Switzerland Non-Insulin Therapies for Diabetes Landscape Analysis

    • 14.1 Switzerland Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 14.2 Switzerland Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    15. Turkey Non-Insulin Therapies for Diabetes Landscape Analysis

    • 15.1 Turkey Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 15.2 Turkey Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Landscape Analysis by Top Countries

      • 16.3.1 Denmark Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

      • 16.3.2 Finland Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

      • 16.3.3 Norway Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

      • 16.3.4 Sweden Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

      • 16.3.6 Iceland Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Landscape Analysis by Top Countries

      • 17.3.1 Belgium Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

      • 17.3.2 Netherlands Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

      • 17.3.3 Luxembourg Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Landscape Analysis by Top Countries

      • 18.3.1 Estonia Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

      • 18.3.2 Latvia Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

      • 18.3.3 Lithuania Non-Insulin Therapies for Diabetes Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Intarcia Therapeutics

      • 19.1.1 Intarcia Therapeutics Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Luye Pharma Group

      • 19.2.1 Luye Pharma Group Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Eli Lilly

      • 19.3.1 Eli Lilly Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Jiangsu Hansoh Pharmaceutical

      • 19.4.1 Jiangsu Hansoh Pharmaceutical Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Merck

      • 19.5.1 Merck Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Sumitomo Dainippon Pharma

      • 19.6.1 Sumitomo Dainippon Pharma Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Novo Nordisk

      • 19.7.1 Novo Nordisk Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Eurofarma

      • 19.8.1 Eurofarma Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Pfizer

      • 19.9.1 Pfizer Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Alkem Labs

      • 19.10.1 Alkem Labs Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 GSK

      • 19.11.1 GSK Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Takeda

      • 19.12.1 Takeda Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 Dong-A Pharmaceutical

      • 19.13.1 Dong-A Pharmaceutical Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 Uni-Bio Science Group

      • 19.14.1 Uni-Bio Science Group Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 Jiangsu Hengrui Medicine

      • 19.15.1 Jiangsu Hengrui Medicine Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    • 19.16 SatRx

      • 19.16.1 SatRx Company Profile and Development Status

      • 19.16.2 Market Performance

      • 19.16.3 Product and Service Introduction

    • 19.17 Servier

      • 19.17.1 Servier Company Profile and Development Status

      • 19.17.2 Market Performance

      • 19.17.3 Product and Service Introduction

    • 19.18 Emisphere

      • 19.18.1 Emisphere Company Profile and Development Status

      • 19.18.2 Market Performance

      • 19.18.3 Product and Service Introduction

    • 19.19 3SBio

      • 19.19.1 3SBio Company Profile and Development Status

      • 19.19.2 Market Performance

      • 19.19.3 Product and Service Introduction

    • 19.20 Geropharm

      • 19.20.1 Geropharm Company Profile and Development Status

      • 19.20.2 Market Performance

      • 19.20.3 Product and Service Introduction

    The List of Tables and Figures (Totals 113 Figures and 140 Tables)

    • Figure Product Picture

    • Figure Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Alpha-glucosidase Inhibitors from 2014 to 2026

    • Figure Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Amylin Agonists from 2014 to 2026

    • Figure Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Biguanides from 2014 to 2026

    • Figure Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Dipeptidyl Peptidase-4 (DPP4) Inhibitors from 2014 to 2026

    • Figure Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Glinides / Meglitinides from 2014 to 2026

    • Figure Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of GLP-1 Analogs / GLP-1 Agonists from 2014 to 2026

    • Figure Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors from 2014 to 2026

    • Figure Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Sulfonylureas from 2014 to 2026

    • Figure Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Thiazolidinediones from 2014 to 2026

    • Figure Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Hospital Pharmacy from 2014 to 2026

    • Figure Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Retail Pharmacies from 2014 to 2026

    • Figure Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Online Pharmacy from 2014 to 2026

    • Figure Europe Non-Insulin Therapies for Diabetes Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Germany Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure UK Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure France Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Non-Insulin Therapies for Diabetes Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Non-Insulin Therapies for Diabetes Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Non-Insulin Therapies for Diabetes

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Non-Insulin Therapies for Diabetes by Different Types from 2014 to 2026

    • Table Consumption Share of Non-Insulin Therapies for Diabetes by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Alpha-glucosidase Inhibitors

    • Figure Market Size and Growth Rate of Amylin Agonists

    • Figure Market Size and Growth Rate of Biguanides

    • Figure Market Size and Growth Rate of Dipeptidyl Peptidase-4 (DPP4) Inhibitors

    • Figure Market Size and Growth Rate of Glinides / Meglitinides

    • Figure Market Size and Growth Rate of GLP-1 Analogs / GLP-1 Agonists

    • Figure Market Size and Growth Rate of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors

    • Figure Market Size and Growth Rate of Sulfonylureas

    • Figure Market Size and Growth Rate of Thiazolidinediones

    • Figure Market Size and Growth Rate of Others

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Non-Insulin Therapies for Diabetes by Different End-Users from 2014 to 2026

    • Table Consumption Share of Non-Insulin Therapies for Diabetes by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of Hospital Pharmacy

    • Figure Market Size and Growth Rate of Retail Pharmacies

    • Figure Market Size and Growth Rate of Online Pharmacy

    • Figure Market Size and Growth Rate of Others

    • Table Europe Non-Insulin Therapies for Diabetes Production by Major Regions

    • Table Europe Non-Insulin Therapies for Diabetes Production Share by Major Regions

    • Figure Europe Non-Insulin Therapies for Diabetes Production Share by Major Countries and Regions in 2014

    • Table Europe Non-Insulin Therapies for Diabetes Consumption by Major Regions

    • Table Europe Non-Insulin Therapies for Diabetes Consumption Share by Major Regions

    • Table Germany Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table UK Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table France Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Italy Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Spain Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Poland Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Russia Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Switzerland Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Turkey Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Non-Insulin Therapies for Diabetes Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Germany Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Germany Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Germany Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table UK Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table UK Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table UK Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table UK Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table France Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table France Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table France Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table France Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Italy Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Italy Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Italy Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Italy Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Spain Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Spain Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Spain Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Spain Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Poland Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Poland Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Poland Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Poland Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Russia Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Russia Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Russia Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Russia Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Switzerland Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Switzerland Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Switzerland Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Turkey Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Turkey Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Turkey Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Insulin Therapies for Diabetes Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Insulin Therapies for Diabetes Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Insulin Therapies for Diabetes Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Non-Insulin Therapies for Diabetes Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Intarcia Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Intarcia Therapeutics

    • Figure Sales and Growth Rate Analysis of Intarcia Therapeutics

    • Figure Revenue and Market Share Analysis of Intarcia Therapeutics

    • Table Product and Service Introduction of Intarcia Therapeutics

    • Table Company Profile and Development Status of Luye Pharma Group

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Luye Pharma Group

    • Figure Sales and Growth Rate Analysis of Luye Pharma Group

    • Figure Revenue and Market Share Analysis of Luye Pharma Group

    • Table Product and Service Introduction of Luye Pharma Group

    • Table Company Profile and Development Status of Eli Lilly

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eli Lilly

    • Figure Sales and Growth Rate Analysis of Eli Lilly

    • Figure Revenue and Market Share Analysis of Eli Lilly

    • Table Product and Service Introduction of Eli Lilly

    • Table Company Profile and Development Status of Jiangsu Hansoh Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Jiangsu Hansoh Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Jiangsu Hansoh Pharmaceutical

    • Figure Revenue and Market Share Analysis of Jiangsu Hansoh Pharmaceutical

    • Table Product and Service Introduction of Jiangsu Hansoh Pharmaceutical

    • Table Company Profile and Development Status of Merck

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Merck

    • Figure Sales and Growth Rate Analysis of Merck

    • Figure Revenue and Market Share Analysis of Merck

    • Table Product and Service Introduction of Merck

    • Table Company Profile and Development Status of Sumitomo Dainippon Pharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sumitomo Dainippon Pharma

    • Figure Sales and Growth Rate Analysis of Sumitomo Dainippon Pharma

    • Figure Revenue and Market Share Analysis of Sumitomo Dainippon Pharma

    • Table Product and Service Introduction of Sumitomo Dainippon Pharma

    • Table Company Profile and Development Status of Novo Nordisk

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novo Nordisk

    • Figure Sales and Growth Rate Analysis of Novo Nordisk

    • Figure Revenue and Market Share Analysis of Novo Nordisk

    • Table Product and Service Introduction of Novo Nordisk

    • Table Company Profile and Development Status of Eurofarma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eurofarma

    • Figure Sales and Growth Rate Analysis of Eurofarma

    • Figure Revenue and Market Share Analysis of Eurofarma

    • Table Product and Service Introduction of Eurofarma

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer

    • Table Company Profile and Development Status of Alkem Labs

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Alkem Labs

    • Figure Sales and Growth Rate Analysis of Alkem Labs

    • Figure Revenue and Market Share Analysis of Alkem Labs

    • Table Product and Service Introduction of Alkem Labs

    • Table Company Profile and Development Status of GSK

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of GSK

    • Figure Sales and Growth Rate Analysis of GSK

    • Figure Revenue and Market Share Analysis of GSK

    • Table Product and Service Introduction of GSK

    • Table Company Profile and Development Status of Takeda

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Takeda

    • Figure Sales and Growth Rate Analysis of Takeda

    • Figure Revenue and Market Share Analysis of Takeda

    • Table Product and Service Introduction of Takeda

    • Table Company Profile and Development Status of Dong-A Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Dong-A Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Dong-A Pharmaceutical

    • Figure Revenue and Market Share Analysis of Dong-A Pharmaceutical

    • Table Product and Service Introduction of Dong-A Pharmaceutical

    • Table Company Profile and Development Status of Uni-Bio Science Group

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Uni-Bio Science Group

    • Figure Sales and Growth Rate Analysis of Uni-Bio Science Group

    • Figure Revenue and Market Share Analysis of Uni-Bio Science Group

    • Table Product and Service Introduction of Uni-Bio Science Group

    • Table Company Profile and Development Status of Jiangsu Hengrui Medicine

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Jiangsu Hengrui Medicine

    • Figure Sales and Growth Rate Analysis of Jiangsu Hengrui Medicine

    • Figure Revenue and Market Share Analysis of Jiangsu Hengrui Medicine

    • Table Product and Service Introduction of Jiangsu Hengrui Medicine

    • Table Company Profile and Development Status of SatRx

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of SatRx

    • Figure Sales and Growth Rate Analysis of SatRx

    • Figure Revenue and Market Share Analysis of SatRx

    • Table Product and Service Introduction of SatRx

    • Table Company Profile and Development Status of Servier

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Servier

    • Figure Sales and Growth Rate Analysis of Servier

    • Figure Revenue and Market Share Analysis of Servier

    • Table Product and Service Introduction of Servier

    • Table Company Profile and Development Status of Emisphere

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Emisphere

    • Figure Sales and Growth Rate Analysis of Emisphere

    • Figure Revenue and Market Share Analysis of Emisphere

    • Table Product and Service Introduction of Emisphere

    • Table Company Profile and Development Status of 3SBio

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of 3SBio

    • Figure Sales and Growth Rate Analysis of 3SBio

    • Figure Revenue and Market Share Analysis of 3SBio

    • Table Product and Service Introduction of 3SBio

    • Table Company Profile and Development Status of Geropharm

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Geropharm

    • Figure Sales and Growth Rate Analysis of Geropharm

    • Figure Revenue and Market Share Analysis of Geropharm

    • Table Product and Service Introduction of Geropharm

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US